AK

Asif Khan Shahnur Khan Pathan

Active Director Director DIN 10960225
DIN 10960225 First appointment Feb 2025 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Asif Khan Shahnur Khan Pathan

Data last updated:

Asif Khan Shahnur Khan Pathan is a Director at Chemistrex Pharmaceuticals Private Limited (since 2025). The company operates in Paper.

DIN 10960225
Primary Designation Director
Industry Paper
First Appointment 20 Feb 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Feb 20252025Active

Board colleagues of Asif Khan Shahnur Khan Pathan

NameDINCompanyDesignation
Abdul Qadeer10960224Chemistrex Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Chemistrex Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Asif Khan Shahnur Khan Pathan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Asif Khan Shahnur Khan Pathan

Asif Khan Shahnur Khan Pathan currently holds 1 directorship: Chemistrex Pharmaceuticals Private Limited (Director, since 20 Feb 2025).

Asif Khan Shahnur Khan Pathan was first appointed on 20 Feb 2025 as Director at Chemistrex Pharmaceuticals Private Limited.

The current boards of Asif Khan Shahnur Khan Pathan's companies include Abdul Qadeer (Chemistrex Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available